Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 tesla

Abstract

Higher-concentration 1.0 M gadobutrol can offer advantages over standard 0.5 M gadopentetate dimeglumine, particularly with respect to delineation between gray and white matter and for the demarcation of highly vascularized tumor tissue on brain PWI performed at 3T.

Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine

“…23 The T1 relaxivity of gadobutrol is approximately 14%-27% higher than that of other Gd chelates, with lower molarity, except 0.5-mol/L gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy), which also has a high T1 relaxivity. 18 In animal models of glioma, gadolinium concentration in the mass after gadobutrol injection is higher than that with other gadolinium chelates. 24 On the basis of these previous studies, we can assume that the CNR of enhancing lesions after gadobutrol administration is much higher than that of other Gd compounds in the clinical field, but no documented data have been reported yet, to our knowledge.…”

“…16,18,21 Gadobutrol had been proved to be a safe MR imaging contrast agent in patients with impaired renal function at doses of Յ0.3 mmol/L/kg of body weight. 22 So far, there have been no reports of nephrogenic systemic fibrosis in association with the administration of gadobutrol.…”

“…[12][13][14][15][16][17] The T1 relaxivity of gadobutrol is approximately 14%-27% higher than that of other 0.5-mol/L Gd chelates. 18 Higher dose administration is known to be more effective in lesion detection, but consideration must be given to reducing the amount of gadolinium administered to the patient because of the risk of contrast-related reactions and nephrogenic systemic fibrosis. 19,20 Gadobutrol had been proved to be a safe MR imaging contrast agent in patients with impaired renal function at doses of Յ0.3 mmol/L/kg of weight, 18 and no nephrogenic systemic fibrosis has been reported so far.…”

“…18 Higher dose administration is known to be more effective in lesion detection, but consideration must be given to reducing the amount of gadolinium administered to the patient because of the risk of contrast-related reactions and nephrogenic systemic fibrosis. 19,20 Gadobutrol had been proved to be a safe MR imaging contrast agent in patients with impaired renal function at doses of Յ0.3 mmol/L/kg of weight, 18 and no nephrogenic systemic fibrosis has been reported so far. 17 At this point, we can postulate that DD gadobutrol is expected to offer better opportunity for further improved enhancement than other Gd contrast agents because of the higher T1 relaxation effect.…”

Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas

“…Another limitation is that rCBV is dependent on field strength, sequence parameters, and relaxivity of the contrast agent used. 22,23 A preinjection of contrast is also desirable to decrease T1 effects that could arise from contrast extravasation and could cause an underestimation of rCBV. 5 DCE imaging can provide absolute measurements of plasma volume and K trans , which could be useful as biomarkers for angiogenesis.…”